We recently published a list of 10 Large Cap Stocks Jim Cramer Can’t Stop Talking About. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against the other large cap stocks Jim Cramer can’t stop talking about.
In a recent episode of Mad Money, Jim Cramer highlights a critical gap in the American education system, which often overlooks financial literacy despite its importance. While students may graduate with extensive knowledge in subjects like chemistry, history, and languages, they rarely receive practical education on managing personal finances. Cramer emphasizes that financial planning, retirement readiness, and investing are seldom covered, leaving many people uninformed about crucial money management skills.
“There is a gaping hole in the American education system, although I hesitate even to call it a system. When you go to high school, they teach you chemistry, geometry, and physics. You have English classes, history classes, and foreign language classes. You can graduate from college speaking three languages with a deep understanding of quantum physics or ancient philosophy. But you know the one thing they almost never teach you in middle school or high school, let alone college? Financial literacy.
And I’m not talking about economics here—you could be an econ major and still learn nothing about financial planning or retirement readiness, let alone investing. Money is just not talked about. Frankly, it’s become the third rail of American education. You’re a thousand times more likely to read Marx’s “Das Kapital” than to read anything about planning a budget or picking stocks.”
Cramer’s mission is to bridge this gap through the CNBC Investing Club, where he and the Charitable Trust provide practical financial guidance. He stresses the significance of retirement planning, noting that while 401(k) plans and Individual Retirement Accounts (IRAs) are key tools for saving, many people lack comprehensive understanding of their benefits and limitations.
“That’s why I’m on a constant mission to teach you how to manage your money, which is what we do every day in the CNBC Investing Club, with the Charitable Trust providing a constant source of examples. When it comes to managing your money, nothing is more important than retirement. Sooner or later, you’re going to stop working—hopefully sooner rather than later, unless you really love your job. I’m betting most of you, even if you don’t own individual stocks, still have some money in a 401(k) plan.
Decades ago, corporate pensions started going the way of the dodo, and now the 401(k) is the main way that Americans save for retirement. They’re offered by your employer, and they’re among the greatest tax-deferred investment vehicles out there, along with the IRA. And I’m not talking about the Irish Republican Army—I’m not even talking about the Inflation Reduction Act, for that matter. I mean the Individual Retirement Account.”
Cramer points out that while contributing to a 401(k) is widely advised, it’s not always the best strategy for everyone. Despite its tax advantages and the ability to defer taxes on contributions, 401(k) plans can have drawbacks, such as hidden fees that diminish returns.
“Hear me out, darn it—you need to know this stuff. Your future self will thank you for getting your retirement funds in order. While you may think you know everything you need to know about these tax-favored accounts, the truth is there’s a lot the so-called experts don’t tell you or don’t want you to know. For example, conventional wisdom says that you absolutely must invest in your 401(k)—you’d have to be a fool not to contribute.
Many experts will even advise you to max out your 401(k) contributions every year if you can afford to. Right now, the maximum contribution is over 20 grand, with room for an additional 7 grand if you’re over 50. It tends to rise gradually over time, usually a little faster than inflation. In 2004, it was $13,000; by 2023, it was $22,500. Either way, that’s a serious chunk of change, even with these contributions coming from your pre-tax income.”
He argues that understanding both the benefits and the shortcomings of these retirement accounts is essential for making informed financial decisions. Cramer encourages individuals to educate themselves about these investment options to ensure their retirement savings are managed effectively.
“However, sometimes I think it can be the wrong approach. I’m not going to sing the praises of the noble 401(k) plan or tell you it’s the key to your financial salvation because 401(k) plans can be a real mixed bag. Sure, they have a couple of really great features, but they also have a lot of bad ones, and those problematic features will eat away at your returns—sometimes through fees that are almost totally hidden from you. I do not like that. So let me lay out the good, the bad, and the ugly of 401(k) plans. Then I’ll tell you whether it makes sense for you to contribute more money to your own 401(k)—maybe there’s a better way for you to invest for retirement.”
At Insider Monkey we are obsessed with the stocks that hedge funds pile into. The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 275% since May 2014, beating its benchmark by 150 percentage points (see more details here).
An array of pharmaceutical pills with the company’s logo on the bottle.
Eli Lilly and Company (NYSE:LLY)
Number of Hedge Fund Investors: 100
Market Capitalization: 861.2B
Jim Cramer recently discussed his approach to evaluating stocks, noting that he currently favors Eli Lilly and Company (NYSE:LLY) over Bristol Myers Squibb Company (NYSE:BMY) due to Eli Lilly’s strong growth prospects, which make its high price-to-earnings ratio less concerning.
“When I look at companies, I might favor Eli Lilly over Bristol, considering the growth rate makes me less concerned about the price-to-earnings ratio. But then Jeff brings me back to earth, reminding me that sometimes a sky-high price-to-earnings ratio can create problems. In the end, we must trust and do what’s right. You can’t become complacent with any stock, even one like Eli Lilly, which I think has the biggest pharmaceutical potential.
I’ve mentioned it twice now, but it’s just on my mind. We could easily become the Eli Lilly fund if it becomes dominant, or the Apple fund if it becomes dominant. What we try to do at all times is avoid swinging from one stock to another, which is why we sometimes recommend trimming.”
In Q2 2024, Eli Lilly and Company (NYSE:LLY) reported strong earnings of $3.92 per share, significantly higher than the $2.64 expected, and revenue of $11.3 billion, exceeding the forecast of $9.83 billion. This impressive performance was driven by successful new drug launches and solid sales across key product lines. Looking ahead, Eli Lilly and Company (NYSE:LLY) is poised for substantial growth, supported by a promising drug pipeline, especially in diabetes and obesity treatments, which are anticipated to boost revenue in the future.
Eli Lilly and Company (NYSE:LLY) has updated its FY 2024 guidance to project earnings per share between $16.10 and $16.60 and revenue between $45.4 billion and $46.6 billion, indicating strong confidence in its continued market expansion. Eli Lilly and Company (NYSE:LLY)’s stock has surged by 64% this year, reflecting strong investor confidence. Eli Lilly and Company (NYSE:LLY)’s strategic acquisitions and partnerships, particularly in oncology and immunology, have strengthened its market position.
Baron Health Care Fund stated the following regarding Eli Lilly and Company (NYSE:LLY) in its Q2 2024 investor letter:
“Shares of global pharmaceutical company Eli Lilly and Company (NYSE:LLY) increased on continued investor enthusiasm around GLP-1 drugs for diabetes and obesity. We remain shareholders. Lilly’s Mounjaro/Zepbound not only offers superb blood sugar control for diabetics but can drive 20%-plus weight loss and likely improve cardiovascular outcomes in both diabetic and non-diabetic obese patients. Lilly is developing next generation drugs, including retatrutide, which drives approximately 25% weight loss, and orforglipron, a daily pill that produces approximately 15% weight loss.
In the U.S. alone, there are 32 million Type 2 diabetics and an additional 105 million obese patients who we estimate would qualify for GLP-1 drugs. Although supply and access are limited near term, we think GLP-1 drugs will become standard of care for both diabetes and obesity and will become a $150 billion-plus category. We see Lilly setting a high efficacy bar and capturing significant long-term market share. We think the adoption of GLP-1s will drive Lilly to triple total revenue by 2030.”
Overall LLY ranks 5th on our list of the large cap stocks Jim Cramer can’t stop talking about. While we acknowledge the potential of LLY as an investment, our conviction lies in the belief that under the radar AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. If you are looking for an AI stock that is more promising than LLY but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.
READ NEXT: $30 Trillion Opportunity: 15 Best Humanoid Robot Stocks to Buy According to Morgan Stanley and Jim Cramer Says NVIDIA ‘Has Become A Wasteland’.
Disclosure: None. This article is originally published at Insider Monkey.
